EU Market Challenges

Having successfully partnered in the launch of 15 significant orphan and niche drug products into the EU market over the last 3 years, Almac have witnessed a steady increase in the number of U.S. companies taking advantage of European Market Opportunities and expect this trend to increase.
This article by Michael Rooney, Senior Business Support Manager at Almac, explores the European marketplace and how it presents a variety of challenges, from complex regulatory frameworks to numerous official working languages and varying country supply chain conditions.
Having supported a range of US clients in their EU launch from as far as 24 months before submission of their MAA to those with shorter time frames, post submission, Michael explains that it’s never too early to start to think about your pharmaceutical product launch. To gain more insight into the EU market, submit your details below.

View Resource
Almac Logo

Commercial Services

Almac Pharma Services provide a wide range of customised commercial services from supporting product launch, manufacturing and / or packaging drug product, to securing supply chain with global serialisation solutions.

Our flexible, quality-led commercial solutions range from orphan drug launches to ongoing high-volume commercial product manufacture, packaging and supply.

Learn More

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies